Abstracts Archive - Page 2005 of 2425 - ACR Meeting Abstracts

Abstract Number: 709 • 2014 ACR/ARHP Annual Meeting
Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (PSQI)in Female with Systemic Lupus Ertyhematosus (SLE).
Lilian Reis¹, Marco Tulio de Mello² and Virginia M. Trevisani³, ¹Internal medicine and therapy, Federal University of Sao Paulo - UNIFESP, SAO PAULO, Brazil, ²Department of Psychobiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ³Federal University of São Paulo, São Paulo Brazil, Brazil
Background/Purpose Despite the fact that sleep disorders are poorly studied, they´re a frequent complain by patients with SLE (62 to 80% related) and others found…
Abstract Number: 708 • 2014 ACR/ARHP Annual Meeting
Determining Risk Factors That Increase Hospitalizations in Patients with Systemic Lupus Erythematosis
Hareth M. Madhoun¹, Wael N. Jarjour², Peter J. Embi³, Erinn M. Hade⁴ and W Neal Roberts Jr⁵, ¹Rheumatology/Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ²Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ³Biomedical Informatics & Internal Medicine, The Ohio State University, Columbus, OH, ⁴College of Medicine Department of Biomedical Informatics, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Dept of Internal Medicine, Division of Rheumatology, University of Louisville, Louisville, KY
Background/Purpose Systemic lupus erythematosis (SLE) is a complex heterogeneous disease which can be associated with significant morbidity and mortality. Hospitalization and readmissions have garnered significant…
Abstract Number: 707 • 2014 ACR/ARHP Annual Meeting
Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody
Samera Vaseer¹, Judith A. James², Aikaterini Thanou³ and Joan T. Merrill⁴, ¹Rheumatology, University Of Oklahoma, Oklahoma City, OK, ²Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Pulmonary involvement is frequent in systemic lupus erythematosus (SLE) and can affect the pleura, pulmonary vasculature, and parenchyma. The prevalence of ILD is lower…
Abstract Number: 681 • 2014 ACR/ARHP Annual Meeting
Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus
Meenakshi Jolly¹, Winston Sequeira², Sarfraz Hasni³, Zulfiqar Ali⁴, Sergio Toloza⁵, Ana M. Bertoli⁶, Ivana Blazevic⁷, Luis M. Vila⁸, Ioana Moldovan⁹, Karina D Torralba¹⁰, Berna Goker¹¹, Josiane Bourré-Tessier¹², S. Navarra¹³, Daniel Wallace¹⁴, Michael H. Weisman¹⁵, Ann E. Clarke¹⁶ and Chi Chiu Mok¹⁷, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Medicine/Rheumatology, Rush University, Chicago, IL, ³NIH, BETHESDA, MD, ⁴NIH, Bethesda, MD, ⁵Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, ⁷University of Buenos Aires, Buenos Aries, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰University of Southern California, LA, CA, ¹¹Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ¹²Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹³University of Santo Tomas Hospital, Manila, Philippines, ¹⁴UCLA, LA, CA, ¹⁵Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁷Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: Hydroxychloroquine (HCQ) has been shown to be beneficial to patients with Systemic Lupus Erythematosus (SLE), however, its effects on the quality of life (QOL)…
Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Eugenia Enriquez Merayo¹, Maria Galindo Izquierdo², Esther Rodriguez-Almaraz³, Maria Martin Lopez², Otto Martin Olivas Vergara⁴, Patricia E. Carreira⁵ and Isabel Mateo⁶, ¹RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, ²RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ³Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ⁵Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
Abstract Number: 698 • 2014 ACR/ARHP Annual Meeting
Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus
James S. Andrews¹, Mary Margaretten², Jennifer Barton², Jinoos Yazdany², Ed Yelin² and Patricia P. Katz³, ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, CA
Background/Purpose: Muscle weakness is common and contributes to physical disability in women with systemic lupus erythematosus (SLE). Recently, the Foundation for the National Institutes of…
Abstract Number: 699 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes
Nimrit Dhillon¹, Dominique Ibanez¹, Dafna D. Gladman² and Murray B. Urowitz², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Osteonecrosis is a serious comorbidity of systemic lupus erythematosus (SLE). The reported frequency of symptomatic osteonecrosis in SLE is variable, ranging from 4% to…
Abstract Number: 697 • 2014 ACR/ARHP Annual Meeting
Venous and Arterial Thrombosis in SLE: Differences in Natural History
Katharine Hickman¹, Laurence S. Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE due to disease activity and co-morbid factors including antiphospholipid antibodies. We separately investigated the natural history of venous vs.…
Abstract Number: 696 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcome of Intestinal Pseudo-Obstruction in Patients with Systemic Lupus Erythematosus
Lingling Zhang, Mengtao Li, Dong Xu, Na Gao, Li Zhang, Yong Hou, Qian Wang and Xiaofeng Zeng, Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
Background/Purpose: Intestinal pseudo-obstruction (IPO) is a rare clinical syndrome characterized by ineffective intestinal motility. IPO has been recently recognized as an uncommon complication of systemic…
Abstract Number: 695 • 2014 ACR/ARHP Annual Meeting
Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome
Andrea Zacarias¹, Javier Narváez², Sergi Heredia¹, Helena Borrell¹, Paula Estrada¹, Alex Roset³, Nestor Arce Gonzalez³, Carmen Gomez Vaquero¹, Olga Capdevila³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To study the prevalence of osteonecrosis (ON) in patients with systemic lupus erythematosus (SLE) and to identify the risk factors for development of this…
Abstract Number: 694 • 2014 ACR/ARHP Annual Meeting
Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics
Maria del Carmen Zamora Medina¹, Hilda Fragoso-Loyo², Martha Morelos³, Juan Jakez-Ocampo⁴, Luis Llorente⁵, Juan Rosas Saucedo⁶ and Yemil Atisha-Fregoso⁷, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ³Radiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁵Immunology and Rheumatology Department, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁷Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Myocarditis is an uncommon manifestation with important morbidity and mortality in patients with Systemic Lupus Erythematosus (SLE). There are scant information about this manifestation…
Abstract Number: 693 • 2014 ACR/ARHP Annual Meeting
Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea
In-Woon Baek¹, Ki-Jo Kim², Yune-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul-Soo Cho¹, ¹Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, ²Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: To determine the factors associated with occurrence of acute myocarditis (AMC) and its outcomes in patients with systemic lupus erythematosus (SLE). Methods: This was…
Abstract Number: 692 • 2014 ACR/ARHP Annual Meeting
Circulating Anti-Ro/SSA Antibodies Are Associated with the Presence of Severe Mitral Regurgitation in Systemic Lupus Erythematosus
Violeta Higuera^1,2, Claudia Hübbe³ and Luis M. Amezcua-Guerra⁴, ¹Juan Badiano #1 Col. Secion XV, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ³Rheumatology, Instituto Nacional de Cardiología, Mexico City, Mexico, ⁴Mexican Board of Rheumatology, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disorder involving multiple organ systems. The frequency of symptomatic heart disease ranges from 5 to 10%,…
Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Eulalia Armengol¹, Gloria Albert¹, Alex Roset³, Patricia Siguenza³, Xavier Juanola⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…
Abstract Number: 689 • 2014 ACR/ARHP Annual Meeting
Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE)
Khaled Alderaan¹, Vuk Sekicki², Laurence S. Magder³ and Michelle Petri⁴, ¹King Fahad Specilaist Hospital, Dammam, Saudi Arabia, ²Medicine, Saint Agnes Hospital, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cataract is the most common ocular damage in SLE. It is the second most frequent item in the SLICC/ACR Damage Index. Apart from cumulative…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].